METASTATIC RENAL CELL CARCINOMA

This study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack a working SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. The main goal is to see if the tumors shrink or stop growing.

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. About 145 adults with various advanced solid tu…

This study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…

This study is testing whether focused, high-dose radiation can control kidney cancer that has spread to a few spots in the body. The goal is to see if this approach can delay or even replace the need for strong medications that affect the whole body. About 123 adults with metasta…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors that have spread. The main goal is to find the safes…

This study tests whether adding the immunotherapy drug nivolumab to standard kidney cancer surgery can stop the cancer from returning. About 819 people with localized kidney cancer took part. The approach aims to boost the immune system to attack any remaining cancer cells after …

This study tests a combination of three drugs (ixazomib, gemcitabine, and doxorubicin) in 30 people with a rare and aggressive kidney cancer that has spread. The goal is to see if the treatment can shrink tumors or stop them from growing. Participants receive the drugs in cycles,…

This study looks at whether keeping blood pressure very low (below 120 mmHg) is better than the usual target (below 140 mmHg) for people with advanced kidney or thyroid cancer starting certain targeted therapies. The goal is to reduce the risk of heart and kidney problems caused …

This study tests a combination of three treatments—an immune-boosting drug injected into a tumor (IL-2), targeted radiation, and the immunotherapy pembrolizumab—in adults with advanced lung, skin, kidney, or head-and-neck cancers that no longer respond to standard immunotherapy. …

This early-phase study tests whether adding a gut bacteria supplement (CBM588) to standard cancer drugs (nivolumab and cabozantinib) can improve treatment for advanced kidney cancer. About 31 adults with metastatic kidney cancer will take the supplement alongside their regular th…

This early-phase study tested whether combining two drugs (cabozantinib and nivolumab) with radiation therapy is safe for people with kidney cancer that has spread to the brain. Only 2 participants were enrolled, and the main goal was to see if they could tolerate the treatment w…

This study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes …

This study tests whether giving precise, high-dose radiation to a limited number of cancer spots (2-5) before starting standard drug therapy can help people with metastatic kidney cancer live longer. About 472 adults with kidney cancer that has spread are taking part. The goal is…

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at controlling the cancer. About 32 participants w…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests whether adding evolocumab to the immunotherapy drug nivolumab can help control metastatic renal cell carcinoma that has not responded to prior treatments. Ten adults with clear-cell kidney cancer will receive the combination, and researchers will monitor safety a…

This early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…

This small study tests whether using a mindfulness app can help people with metastatic kidney cancer cope better with their disease. About 21 patients will use the app and report on their anxiety, depression, and quality of life. The goal is to see if this approach is practical a…

This study aimed to see if limiting eating to a 10-hour window each day could improve how well immunotherapy works in people with advanced head and neck or kidney cancer. Researchers wanted to know if this eating pattern changes gut bacteria and boosts treatment response. The stu…

This study follows about 468 people with metastatic kidney cancer to see how their treatment choices and quality of life change over time in real-world clinics and hospitals. It does not test a new drug or procedure. Instead, it collects information from patient questionnaires an…

This study tests a small implantable device that releases tiny amounts of 19 different cancer drugs directly into kidney tumors. The device is placed and removed during planned surgery. The goal is to see if this approach is safe and can help doctors learn which drugs work best f…

This study watches 224 adults with advanced kidney cancer who are already taking cabozantinib (alone or with nivolumab) as their first treatment. Researchers track how often patients need to lower doses, pause, or stop treatment due to side effects. No new drugs are tested; the g…